利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

401 条记录 (耗时 0.04 秒)

    Prostamide-containing intraocular implants and methods of use thereof
    4.
    发明授权
    Prostamide-containing intraocular implants and methods of use thereof 有权
    含前列腺素的眼内植入物及其使用方法

    公开(公告)号：US09492316B2

    公开(公告)日：2016-11-15

    申请号：US14529526

    申请日：2014-10-31

    申请人： Allergan, Inc.

    发明人： Alazar N. Ghebremeskel ,  Michael R. Robinson

    IPC分类号： A61K9/52 ,  A61K9/58 ,  A61K31/765 ,  A61F9/00 ,  A61K31/165 ,  A61K9/00 ,  A61K47/10 ,  A61K47/34 ,  A61K9/16 ,  A61K31/5575

    CPC分类号： A61K31/5575 ,  A61F9/0017 ,  A61K9/0051 ,  A61K9/1647 ,  A61K31/165 ,  A61K47/10 ,  A61K47/34

    摘要： Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. Methods for making and using the implants to reduce ocular hypertension and intraocular pressure in a patient are described.

    摘要翻译： 在眼睛中生物降解并有效降低眼睛持续时间内的眼内压的含有前列腺素的眼内植入物。 植入物通常含有前列腺酰胺，例如比马前列素，以及至少三种不同的生物可降解聚合物，其选自聚丙交酯和聚（丙交酯 - 共 - 乙交酯）聚合物，并被优化用于放置在眼前房， 室角度。 描述了制造和使用植入物以减少患者中的高眼压和眼内压的方法。

    Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles
    5.
    发明授权
    Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles 有权
    使用智能聚合物纳米颗粒的水分散性口服，肠胃外和局部用于水溶性差的药物

    公开(公告)号：US08715741B2

    公开(公告)日：2014-05-06

    申请号：US13650273

    申请日：2012-10-12

    申请人： Anirban Maitra ,  Georg Feldmann ,  Savita Bisht

    发明人： Anirban Maitra ,  Georg Feldmann ,  Savita Bisht

    IPC分类号： A61K9/00 ,  A61K9/58

    CPC分类号： A61K9/146 ,  A61K9/19 ,  A61K9/5138 ,  A61K47/6933 ,  A61K47/6935 ,  B01J13/14 ,  B01J13/18 ,  B82Y5/00

    摘要： Polymeric nanoparticles with a hydrophobic core and a hydrophilic shell are formed from: 1) N-isopropylacrylamide (NIPAAM), at a molar ratio of about 50% to about 90%, and preferably 60% for specific delivery routes such as oral or parenteral; either water-soluble vinyl derivatives like vinylpryolidone (VP) or vinyl acetate (VA), or water insoluble vinyl derivatives like methyl methacrylate (MMA) or styrene (ST), at a molar ratio of about 10% to about 30%; and acrylic acid (AA), at a molar ration of about 10% to about 30%.

    摘要翻译： 具有疏水核心和亲水壳的聚合物纳米颗粒由以下物质形成：1）N-异丙基丙烯酰胺（NIPAAM），其摩尔比为约50％至约90％，优选为60％，用于特定的输送途径如口服或肠胃外; 水溶性乙烯基衍生物，例如乙烯基稠聚物（VP）或乙酸乙烯酯（VA），或水不溶性乙烯基衍生物，如甲基丙烯酸甲酯（MMA）或苯乙烯（ST）），摩尔比为约10％至约30％ 和丙烯酸（AA），摩尔比为约10％至约30％。

    Stable lipophilic emulsions for acrylic coating and method of making
    6.
    发明授权
    Stable lipophilic emulsions for acrylic coating and method of making 失效
    用于丙烯酸涂料的稳定的亲脂性乳液及其制备方法

    公开(公告)号：US08591920B2

    公开(公告)日：2013-11-26

    申请号：US11163735

    申请日：2005-10-28

    申请人： Charles Signorino

    发明人： Charles Signorino

    IPC分类号： A61K9/00 ,  A61K9/127 ,  A61K9/66 ,  A61K9/54 ,  A61K9/58 ,  A61K9/48 ,  A61K9/20

    CPC分类号： A61K9/2846 ,  A61K9/1075 ,  A61K47/14 ,  A61K47/26

    摘要： Emulsions of lipophiles such as glycerol monostearate which are compatible with acrylic copolymer emulsions are made stable by using an emulsion stabilizer such as polysorbate 80 in an amount by weight between 1% and 5% of the lipophile and homogenizing the emulsion wherein the emulsion micelles are less than 50 microns. The ability to make a stable emulsion of a lipophile is important in the coating process as it enables preparation and shipment of the lipophilic emulsion to the coater rather than the preparation of a lipophilic emulsion at the time of the coating process which involves a heating and cooling process.

    摘要翻译： 使用与丙烯酸共聚物乳液相容的亲油亲油（如单硬脂酸甘油酯）的乳液通过使用乳液稳定剂如聚山梨酯80重量比在亲脂体的1％至5％之间而使其稳定，并使乳液均匀化，其中乳液胶束较少 超过50微米。 制备亲油性稳定乳液的能力在涂布过程中是重要的，因为它能够将亲油性乳液制备和运输到涂布机，而不是在涂布过程中制备亲脂性乳液，其包括加热和冷却 处理。

    Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles
    8.
    发明授权
    Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles 失效
    吡啶-2-基甲基亚磺酰基-1H-苯并咪唑的口服给药形式

    公开(公告)号：US08465767B2

    公开(公告)日：2013-06-18

    申请号：US12153585

    申请日：2008-05-21

    申请人： Rango Dietrich ,  Hartmut Ney

    发明人： Rango Dietrich ,  Hartmut Ney

    IPC分类号： A61K9/58 ,  A61K9/54 ,  A61K31/4439

    CPC分类号： A61K9/2027 ,  A61K9/2846

    摘要： The invention relates to an oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles and their salts, which comprises the active compound together with tablet disintegrants and is provided with a film coating customary per se for sustained-release compositions.

    摘要翻译： 本发明涉及吡啶-2-基甲基亚磺酰基-1H-苯并咪唑及其盐的口服给药形式，其包含活性化合物和片剂崩解剂，并且为缓释组合物提供本身常用的薄膜包衣。

    CONTROLLED-RELEASE PHARMACEUTICAL COMPOSITION INCLUDING TAMSULOSIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND ORAL FORMULATION INCLUDING THE SAME
    9.
    发明申请
    CONTROLLED-RELEASE PHARMACEUTICAL COMPOSITION INCLUDING TAMSULOSIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND ORAL FORMULATION INCLUDING THE SAME 审中-公开

    公开(公告)号：US20130052264A1

    公开(公告)日：2013-02-28

    申请号：US13695814

    申请日：2011-04-27

    申请人： Ho-Jin Chung ,  Sang-Yeob Park ,  Chaul-Min Pai

    发明人： Ho-Jin Chung ,  Sang-Yeob Park ,  Chaul-Min Pai

    IPC分类号： A61K9/58 ,  A61K9/32 ,  A61P13/02 ,  A61K9/08 ,  A61K31/18 ,  A61K9/14 ,  A61K9/16

    CPC分类号： A61K31/18 ,  A61K9/5073 ,  A61K9/5078 ,  A61K9/5084

    摘要： A controlled-release pharmaceutical composition including first and second groups of microparticles, each of the microparticles including a core including tamsulosin or pharmaceutically acceptable salts thereof, a controlled-release polymer coating layer formed on the core, and an enteric polymer outer layer formed on the controlled-release polymer coating layer, wherein the average thickness of the controlled-release polymer coating layer is different in each of the first and second groups of microparticles, and an oral formulation including the same, are provided. This pharmaceutical composition can easily control the extent of release of an active ingredient depending on changes in pH in the intestinal tract and the release pattern of the active ingredient in the small intestine, thus preventing the active ingredient from being rapidly transferred into the blood to thereby minimize side-effects, and maintaining the effective blood concentration of the active ingredient for a predetermined period of time. Furthermore, this composition can shield the bitter taste of the active ingredient even when exposed to the inside of the mouth, thus increasing the therapeutic effects for patients upon oral administration.